Abstract
The patent application WO201268820 claims a new class of polymyxin derivatives with potent antibacterial activity, especially toward Gram-negative pathogens. Compared to parent polymyxin B (PMB), the new derivatives have more potent antibacterial activity, as well as reduced cytotoxicity against human renal cells.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / pharmacology*
-
Drug Design*
-
Gram-Negative Bacteria / drug effects
-
Gram-Negative Bacterial Infections / drug therapy
-
Humans
-
Patents as Topic
-
Polymyxin B / analogs & derivatives
-
Polymyxin B / pharmacology
-
Polymyxins / adverse effects
-
Polymyxins / chemistry
-
Polymyxins / pharmacology*
Substances
-
Anti-Bacterial Agents
-
Polymyxins
-
Polymyxin B